Kuderer, N. M., Desai, A., Lustberg, M. B. & Lyman, G. H. Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat. Rev. Clin. Oncol. 19, 681–697 (2022).
Google Scholar
National Coalition for Cancer Survivorship. State of Survivorship Survey: 2022 https://canceradvocacy.org/2022-state-of-cancer-survivorship-survey/ (2022).
Vaz-Luis, I. et al. Long-term longitudinal patterns of patient-reported fatigue after breast cancer: a group-based trajectory analysis. J. Clin. Oncol. 40, 2148–2162 (2022).
Google Scholar
Bower, J. E. Cancer-related fatigue — mechanisms, risk factors, and treatments. Nat. Rev. Clin. Oncol. 11, 597–609 (2014).
Google Scholar
Thong, M. S. Y. et al. Cancer-related fatigue: causes and current treatment options. Curr. Treat. Options Oncol. 21, 17 (2020).
Google Scholar
Smeland, K. B. et al. Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity. Bone Marrow Transpl. 54, 607–610 (2019).
Google Scholar
Reinertsen, K. V. et al. Predictors and course of chronic fatigue in long-term breast cancer survivors. J. Cancer Surviv. 4, 405–414 (2010).
Google Scholar
Husson, O. et al. Variation in fatigue among 6011 (long-term) cancer survivors and a normative population: a study from the population-based PROFILES registry. Support. Care Cancer 23, 2165–2174 (2015).
Google Scholar
Steen, R. et al. A study of chronic fatigue in Norwegian cervical cancer survivors. Gynecol. Oncol. 146, 630–635 (2017).
Google Scholar
Berger, A. M. et al. Cancer-related fatigue, version 2.2015. J. Natl Compr. Canc. Netw. 13, 1012–1039 (2015).
Google Scholar
Berger, A. M. & Mooney, K. Dissemination and implementation of guidelines for cancer-related fatigue. J. Natl Compr. Canc. Netw. 14, 1336–1338 (2016).
Google Scholar
Bower, J. E. et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J. Clin. Oncol. 32, 1840–1850 (2014).
Google Scholar
Fabi, A. et al. Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment. Ann. Oncol. 31, 713–723 (2020).
Google Scholar
Jacobsen, P. B. et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J. Pain Symptom Manag. 18, 233–242 (1999).
Google Scholar
Broeckel, J. A. et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 16, 1689–1696 (1998).
Google Scholar
Ryan, J. L. et al. Mechanisms of cancer-related fatigue. Oncologist 12, 22–34 (2007).
Google Scholar
Bower, J. E. & Lamkin, D. M. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav. Immun. 30, S48–S57 (2013).
Google Scholar
Lee, S. et al. Prediction of breast cancer treatment-induced fatigue by machine learning using genome-wide association data. JNCI Cancer Spectr. 4, pkaa039 (2020).
Google Scholar
Charalambous, A. et al. Cancer-related fatigue and sleep deficiency in cancer care continuum: concepts, assessment, clusters, and management. Support. Care Cancer 27, 2747–2753 (2019).
Google Scholar
Goedendorp, M. M. et al. Development of fatigue in cancer survivors: a prospective follow-up study from diagnosis into the year after treatment. J. Pain Symptom Manag. 45, 213–222 (2013).
Google Scholar
O’Higgins, C. M. et al. The pathophysiology of cancer-related fatigue: current controversies. Support. Care Cancer 26, 3353–3364 (2018).
Google Scholar
Eyob, T. et al. Impact of chemotherapy on cancer-related fatigue and cytokines in 1312 patients: a systematic review of quantitative studies. Curr. Opin. Support. Palliat. Care 10, 165–179 (2016).
Google Scholar
Dantzer, R. et al. The neuroimmune basis of fatigue. Trends Neurosci. 37, 39–46 (2014).
Google Scholar
Inglis, J. E. et al. Nutritional interventions for treating cancer-related fatigue: a qualitative review. Nutr. Cancer 71, 21–40 (2019).
Google Scholar
Bower, J. E., Crosswell, A. D. & Slavich, G. M. Childhood adversity and cumulative life stress: risk factors for cancer-related fatigue. Clin. Psychol. Sci. 2, 108–115 (2014).
Google Scholar
Bower, J. E. et al. Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer. Cancer 127, 1334–1344 (2021).
Google Scholar
Bower, J. E. et al. Fatigue after breast cancer treatment: biobehavioral predictors of fatigue trajectories. Health Psychol. 37, 1025–1034 (2018).
Google Scholar
Di Meglio, A. et al. Development and validation of a predictive model of severe fatigue after breast cancer diagnosis: toward a personalized framework in survivorship care. J. Clin. Oncol. 40, 1111–1123 (2022).
Google Scholar
Hammermuller, C. et al. Depression, anxiety, fatigue, and quality of life in a large sample of patients suffering from head and neck cancer in comparison with the general population. BMC Cancer 21, 94 (2021).
Google Scholar
Brown, L. F. & Kroenke, K. Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 50, 440–447 (2009).
Google Scholar
Armstrong, T. S. et al. Association of genetic variants with fatigue in patients with malignant glioma. Neurooncol. Pract. 5, 122–128 (2018).
Google Scholar
Jean-Pierre, P. et al. Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12, 11–21 (2007).
Google Scholar
Mendoza, T. R. et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85, 1186–1196 (1999).
Google Scholar
Yellen, S. B. et al. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J. Pain Symptom Manag. 13, 63–74 (1997).
Google Scholar
Stein, K. D. et al. Further validation of the multidimensional fatigue symptom inventory-short form. J. Pain Symptom Manag. 27, 14–23 (2004).
Google Scholar
Hann, D. M. et al. Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory. Qual. Life Res. 7, 301–310 (1998).
Google Scholar
Chow, R. et al. Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis. BMJ Support. Palliat. Care https://doi.org/10.1136/bmjspcare-2021-003244 (2021).
Google Scholar
Popescu, R. A. et al. Supportive care: low cost, high value. Am. Soc. Clin. Oncol. Educ. Book 41, 1–11 (2021).
Google Scholar
Lawrence, J. A. et al. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J. Cancer Surviv. 10, 176–184 (2016).
Google Scholar
Bruera, E. et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J. Clin. Oncol. 25, 3475–3481 (2007).
Google Scholar
Paulsen, O. et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J. Clin. Oncol. 32, 3221–3228 (2014).
Google Scholar
Yennurajalingam, S. et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J. Clin. Oncol. 31, 3076–3082 (2013).
Google Scholar
Yennu, S. V. V. et al. High/low dose dexamethasone with physical activity for cancer-related fatigue in patients with advanced cancer: a phase II randomized double blind study. J. Clin. Oncol. 37 (Suppl. 31), 110 (2019).
Google Scholar
Sadeghian, M. et al. Ginseng and cancer-related fatigue: a systematic review of clinical trials. Nutr. Cancer 73, 1270–1281 (2021).
Google Scholar
Mustian, K. M. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 3, 961–968 (2017).
Google Scholar
Dennett, A. M. et al. Multidisciplinary, exercise-based oncology rehabilitation programs improve patient outcomes but their effects on healthcare service-level outcomes remain uncertain: a systematic review. J. Physiother. 67, 12–26 (2021).
Google Scholar
David, A., Hausner, D. & Frenkel, M. Cancer-related fatigue-is there a role for complementary and integrative medicine? Curr. Oncol. Rep. 23, 145 (2021).
Google Scholar
Gielissen, M. F. et al. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J. Clin. Oncol. 24, 4882–4887 (2006).
Google Scholar
Poort, H. et al. Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial. Ann. Oncol. 31, 115–122 (2020).
Google Scholar
Seiler, A. et al. eHealth and mHealth interventions in the treatment of fatigued cancer survivors: a systematic review and meta-analysis. Psychooncology 26, 1239–1253 (2017).
Google Scholar
Foster, C. et al. A web-based intervention (RESTORE) to support self-management of cancer-related fatigue following primary cancer treatment: a multi-centre proof of concept randomised controlled trial. Support. Care Cancer 24, 2445–2453 (2016).
Google Scholar
Maihofner, C. et al. Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. Support. Care Cancer 29, 4223–4238 (2021).
Google Scholar
Salat, K. Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy. Pharmacol. Rep. 72, 486–507 (2020).
Google Scholar
Seretny, M. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155, 2461–2470 (2014).
Google Scholar
Coradini, P. P. et al. Ototoxicity from cisplatin therapy in childhood cancer. J. Pediatr. Hematol. Oncol. 29, 355–360 (2007).
Google Scholar
Landier, W. Ototoxicity and cancer therapy. Cancer 122, 1647–1658 (2016).
Google Scholar
Hu, S. et al. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin. Cancer Res. 25, 6295–6301 (2019).
Google Scholar
Chan, A. et al. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support. Care Cancer 27, 3729–3737 (2019).
Google Scholar
St Germain, D. C. et al. Chemotherapy-induced peripheral neuropathy: identifying the research gaps and associated changes to clinical trial design. Cancer 126, 4602–4613 (2020).
Google Scholar
Loprinzi, C. L. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J. Clin. Oncol. 38, 3325–3348 (2020).
Google Scholar
Jordan, B. et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann. Oncol. 31, 1306–1319 (2020).
Google Scholar
Hertz, D. L. et al. Patient-centric decision framework for treatment alterations in patients with chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat. Rev. 99, 102241 (2021).
Google Scholar
Mizrahi, D. et al. Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. Support. Care Cancer 30, 5965–5974 (2022).
Google Scholar
Tan, A. C. et al. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade. Support. Care Cancer 27, 4771–4777 (2019).
Google Scholar
McCrary, J. M. et al. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support. Care Cancer 25, 3485–3493 (2017).
Google Scholar
Pfeiffer, P. et al. Calmangafodipir for prevention of oxaliplatin-induced peripheral neuropathy: two placebo-controlled, randomized phase 3 studies (POLAR-A/POLAR-M). JNCI Cancer Spectr. 6, pkac075 (2022).
Google Scholar
Smith, E. M. et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309, 1359–1367 (2013).
Google Scholar
Zirpoli, G. R. et al. Supplement use and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221): the DELCaP study. J. Natl Cancer Inst. 109, djx098 (2017).
Google Scholar
Hershman, D. L. et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J. Clin. Oncol. 31, 2627–2633 (2013).
Google Scholar
Ambrosone, C. B. et al. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). J. Clin. Oncol. 38, 804–814 (2020).
Google Scholar
Greenlee, H. et al. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res. Treat. 156, 453–464 (2016).
Google Scholar
Lu, W. et al. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer survivors: a randomized controlled pilot trial. Oncologist 25, 310–318 (2020).
Google Scholar
Tsuyuki, S. et al. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group. Breast Cancer Res. Treat. 160, 61–67 (2016).
Google Scholar
Tsuyuki, S. et al. Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy. Breast 47, 22–27 (2019).
Google Scholar
Kanbayashi, Y. et al. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a prospective self-controlled trial. Breast 49, 219–224 (2020).
Google Scholar
Kanzawa-Lee, G. A. et al. Exercise effects on chemotherapy-induced peripheral neuropathy: a comprehensive integrative review. Cancer Nurs. 43, E172–E185 (2020).
Google Scholar
Kleckner, I. R. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support. Care Cancer 26, 1019–1028 (2018).
Google Scholar
Streckmann, F. et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann. Oncol. 25, 493–499 (2014).
Google Scholar
Streckmann, F. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med. 44, 1289–1304 (2014).
Google Scholar
Mayo, S. J. et al. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support. Care Cancer 29, 2821–2840 (2021).
Google Scholar
Janelsins, M. C. et al. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int. Rev. Psychiatry 26, 102–113 (2014).
Google Scholar
Williams, A. M., Zent, C. S. & Janelsins, M. C. What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br. J. Haematol. 174, 835–846 (2016).
Google Scholar
Lange, M. et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann. Oncol. 30, 1925–1940 (2019).
Google Scholar
Wefel, J. S. et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703–708 (2011).
Google Scholar
Mounier, N. M. et al. Chemotherapy-induced cognitive impairment (CICI): an overview of etiology and pathogenesis. Life Sci. 258, 118071 (2020).
Google Scholar
Janelsins, M. C. et al. Longitudinal changes in cognitive function in a nationwide cohort study of patients with lymphoma treated with chemotherapy. J. Natl Cancer Inst. 114, 47–59 (2021).
Google Scholar
Magnuson, A. et al. Cognitive function in older adults with cancer: assessment, management, and research opportunities. J. Clin. Oncol. 39, 2138–2149 (2021).
Google Scholar
Mayo, S. J. et al. Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 55, 918–928 (2020).
Google Scholar
Mayo, S. J. et al. Late cognitive outcomes among allogeneic stem cell transplant survivors: follow-up data from a 6-year longitudinal study. Support. Care Cancer 29, 2621–2630 (2021).
Google Scholar
Ahles, T. A., Root, J. C. & Ryan, E. L. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J. Clin. Oncol. 30, 3675–3686 (2012).
Google Scholar
Von Ah, D. et al. Cancer, cognitive impairment, and work-related outcomes: an integrative review. Oncol. Nurs. Forum 43, 602–616 (2016).
Google Scholar
Duijts, S. F. et al. Cancer-related cognitive impairment and patients’ ability to work: a current perspective. Curr. Opin. Support. Palliat. Care 11, 19–23 (2017).
Google Scholar
Mandelblatt, J. S. et al. Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J. Clin. Oncol. 32, 1909–1918 (2014).
Google Scholar
Huskisson, E., Maggini, S. & Ruf, M. The influence of micronutrients on cognitive function and performance. J. Int. Med. Res. 35, 1–19 (2007).
Google Scholar
Mancuso, A. et al. Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann. Oncol. 17, 146–150 (2006).
Google Scholar
Mandelblatt, J. S. et al. Cancer-related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study. J. Clin. Oncol. 36, JCO1800140 (2018).
Google Scholar
Ahles, T. A. et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12, 612–619 (2003).
Google Scholar
Cheng, H. et al. The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am. J. Transl. Res. 8, 5087–5097 (2016).
Google Scholar
Lyon, D. E. et al. Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer. J. Neuroimmunol. 301, 74–82 (2016).
Google Scholar
Pomykala, K. L. et al. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav. 7, 511–523 (2013).
Google Scholar
Yap, N. Y. et al. Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer. Breast Cancer Res. Treat. 183, 683–696 (2020).
Google Scholar
Tevaarwerk, A. et al. Survivorship, version 1.2021. J. Natl Compr. Canc Netw. 19, 676–685 (2021).
Google Scholar
Giesinger, J. M. et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J. Clin. Epidemiol. 69, 79–88 (2016).
Google Scholar
Henneghan, A. M. et al. Measuring self-reported cancer-related cognitive impairment: recommendations from the Cancer Neuroscience Initiative Working Group. J. Natl Cancer Inst. 113, 1625–1633 (2021).
Google Scholar
Fernandes, H. A., Richard, N. M. & Edelstein, K. Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review. Support. Care Cancer 27, 3253–3279 (2019).
Google Scholar
Vardy, J. L. et al. A randomised controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairment. J. Cancer Surviv. https://doi.org/10.1007/s11764-022-01261-5 (2022).
Google Scholar
Campbell, K. L. et al. The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: systematic review of randomized controlled trials. Phys. Ther. 100, 523–542 (2020).
Google Scholar
Farahani, M. A. et al. The effect of mind-body exercise on cognitive function in cancer survivors: a systematic review. Can. Oncol. Nurs. J. 32, 38–48 (2022).
Google Scholar
Kohli, S. et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115, 2605–2616 (2009).
Google Scholar
Brown, P. D. et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-oncology 15, 1429–1437 (2013).
Google Scholar
Dos Santos, M. et al. Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: a 3-arm randomized trial. Cancer 126, 5328–5336 (2020).
Google Scholar
Bray, V. J. et al. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J. Clin. Oncol. 35, 217–225 (2017).
Google Scholar
Desai, A. et al. Takotsubo cardiomyopathy in cancer patients. Cardiooncology 5, 7 (2019).
Google Scholar
Alexandre, J. et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-Oncology Guidelines. J. Am. Heart Assoc. 9, e018403 (2020).
Google Scholar
Herrmann, J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat. Rev. Cardiol. 17, 474–502 (2020).
Google Scholar
Belzile-Dugas, E. & Eisenberg, M. J. Radiation-induced cardiovascular disease: review of an underrecognized pathology. J. Am. Heart Assoc. 10, e021686 (2021).
Google Scholar
Marinescu, D. C. et al. Integration and application of Clinical Practice Guidelines for the diagnosis of idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis. Chest 162, 614–629 (2022).
Google Scholar
Curigliano, G. et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol. 31, 171–190 (2020).
Google Scholar
Armenian, S. H. et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 35, 893–911 (2017).
Google Scholar
Ligibel, J. A., Bohlke, K. & Alfano, C. M. Exercise, diet, and weight management during cancer treatment: ASCO Guideline Summary and Q&A. JCO Oncol. Pract. 18, 695–697 (2022).
Google Scholar
Campbell, K. L. et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med. Sci. Sports Exerc. 51, 2375–2390 (2019).
Google Scholar
Zardavas, D. et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J. Clin. Oncol. 35, 878–884 (2017).
Google Scholar
Lenihan, D. J. et al. The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study. J. Card. Fail. 22, 433–438 (2016).
Google Scholar
Kalay, N. et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 48, 2258–2262 (2006).
Google Scholar
Heck, S. L. et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation 143, 2431–2440 (2021).
Google Scholar
Akpek, M. et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur. J. Heart Fail. 17, 81–89 (2015).
Google Scholar
Shahid, I. et al. Meta-analysis evaluating the use of statins to attenuate cardiotoxicity in cancer patients receiving anthracyclines and trastuzumab-based chemotherapy. Am. J. Cardiol. 156, 142–145 (2021).
Google Scholar
Cardinale, D. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2474–2481 (2006).
Google Scholar
Livi, L. et al. Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial. JAMA Oncol. 7, 1544–1549 (2021).
Google Scholar
Dhamija, E. et al. Chemotherapy-induced pulmonary complications in cancer: significance of clinicoradiological correlation. Indian J. Radiol. Imaging 30, 20–26 (2020).
Google Scholar
Libura, J. et al. Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene. Eur. Respir. J. 19, 912–918 (2002).
Google Scholar
Maldonado, F., Limper, A. H. & Cass, A. S. Pulmonary Toxicity Associated with Systemic Antineoplastic Therapy: Clinical Presentation, Diagnosis, and Treatment https://www.uptodate.com/contents/pulmonary-toxicity-associated-with-systemic-antineoplastic-therapy-clinical-presentation-diagnosis-and-treatment (2021).
Fujimoto, D. et al. Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer. PLoS One 11, e0168465 (2016).
Google Scholar
Vahid, B. & Marik, P. E. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133, 528–538 (2008).
Google Scholar
Limper, A. H. Chemotherapy-induced lung disease. Clin. Chest Med. 25, 53–64 (2004).
Google Scholar
Jules-Elysee, K. & White, D. A. Bleomycin-induced pulmonary toxicity. Clin. Chest Med. 11, 1–20 (1990).
Google Scholar
Blum, R. H., Carter, S. K. & Agre, K. A clinical review of bleomycin — a new antineoplastic agent. Cancer 31, 903–914 (1973).
Google Scholar
Kawai, K. et al. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn. J. Clin. Oncol. 28, 546–550 (1998).
Google Scholar
O’Sullivan, J. M. et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncol. 14, 91–96 (2003).
Google Scholar
Haugnes, H. S. et al. Pulmonary function in long-term survivors of testicular cancer. J. Clin. Oncol. 27, 2779–2786 (2009).
Google Scholar
O’Driscoll, B. R. et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N. Engl. J. Med. 323, 378–382 (1990).
Google Scholar
White, D. A. et al. Acute chest pain syndrome during bleomycin infusions. Cancer 59, 1582–1585 (1987).
Google Scholar
Uzel, I. et al. Delayed onset bleomycin-induced pneumonitis. Urology 66, 195 (2005).
Google Scholar
FDA. Bleomycin Sulfate for Injection, USP Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf (2010).
Freites-Martinez, A. et al. Using the common terminology criteria for adverse events (CTCAE – Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 112, 90–92 (2021).
Google Scholar
Camus, P. et al. Drug-induced and iatrogenic infiltrative lung disease. Clin. Chest Med. 25, 479–519 (2004).
Google Scholar
Raghu, G. et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 205, e18–e47 (2022).
Google Scholar
Desai, A. et al. Antibody-drug conjugates: a promising novel therapeutic approach in lung cancer. Lung Cancer 163, 96–106 (2022).
Google Scholar
Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2019. J. Natl Compr. Canc Netw. 17, 255–289 (2019).
Google Scholar
Tarantino, P. et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 7, 1873–1881 (2021).
Google Scholar
Flaherty, K. R. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 381, 1718–1727 (2019).
Google Scholar
King, T. E. Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083–2092 (2014).
Google Scholar
Bober, S. L. & Varela, V. S. Sexuality in adult cancer survivors: challenges and intervention. J. Clin. Oncol. 30, 3712–3719 (2012).
Google Scholar
Melisko, M. E. & Narus, J. B. Sexual function in cancer survivors: updates to the NCCN Guidelines for Survivorship. J. Natl Compr. Canc Netw. 14, 685–689 (2016).
Google Scholar
Smith, T., Kingsberg, S. A. & Faubion, S. Sexual dysfunction in female cancer survivors: addressing the problems and the remedies. Maturitas 165, 52–57 (2022).
Google Scholar
van Basten, J. P. et al. Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy. J. Clin. Oncol. 15, 2442–2448 (1997).
Google Scholar
Pallotti, F. et al. Long-term follow up of the erectile function of testicular cancer survivors. Front. Endocrinol. 10, 196 (2019).
Google Scholar
Jonker-Pool, G. et al. Sexual functioning after treatment for testicular cancer: comparison of treatment modalities. Cancer 80, 454–464 (1997).
Google Scholar
Barkatz, J. et al. Sexual dysfunctions of patients treated with orchidectmoy, chemotherapy and retroperitoneal lymphadenectomy, need for systematic andrological care? [French]. Bull. Cancer 106, 915–922 (2019).
Google Scholar
Katz, A., Agrawal, L. S. & Sirohi, B. Sexuality after cancer as an unmet need: addressing disparities, achieving equality. Am. Soc. Clin. Oncol. Educ. Book 42, 1–7 (2022).
Google Scholar
Robinson, P. J. et al. Aromatase inhibitors are associated with low sexual desire causing distress and fecal incontinence in women: an observational study. J. Sex. Med. 14, 1566–1574 (2017).
Google Scholar
Baumgart, J. et al. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 20, 162–168 (2013).
Google Scholar
Smedsland, S. K. et al. Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey. Breast Cancer Res. Treat. 193, 139–149 (2022).
Google Scholar
Pizzol, D. et al. Prevalence of erectile dysfunction in male survivors of cancer: a systematic review and meta-analysis of cross-sectional studies. Br. J. Gen. Pract. 71, e372–e380 (2021).
Google Scholar
Carter, J. et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J. Clin. Oncol. 36, 492–511 (2018).
Google Scholar
Cold, S. et al. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J. Natl Cancer Inst. 114, 1347–1354 (2022).
Google Scholar
ACOG Committee Opinion No. 659. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet. Gynecol. 127, e93–e96 (2016).
Google Scholar
Chung, E. & Brock, G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J. Sex. Med. 10, 102–111 (2013).
Google Scholar
Wittmann, D. et al. Guidelines for sexual health care for prostate cancer patients: recommendations of an International Panel. J. Sex. Med. 19, 1655–1669 (2022).
Google Scholar
Lee, S. J. et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 24, 2917–2931 (2006).
Google Scholar
Paoli, D. et al. Spermatogenesis in Hodgkin’s lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Hum. Reprod. 31, 263–272 (2016).
Google Scholar
Oktay, K., Harvey, B. E. & Loren, A. W. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update Summary. J. Oncol. Pract. 14, 381–385 (2018).
Google Scholar
Lambertini, M. et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 31, 1664–1678 (2020).
Google Scholar
Spears, N. et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum. Reprod. Update 25, 673–693 (2019).
Google Scholar
Poorvu, P. D. et al. Cancer treatment-related infertility: a critical review of the evidence. JNCI Cancer Spectr. 3, pkz008 (2019).
Google Scholar
van Dorp, W. et al. Genetic variation may modify ovarian reserve in female childhood cancer survivors. Hum. Reprod. 28, 1069–1076 (2013).
Google Scholar
Su, H. I. et al. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil. Steril. 94, 645–654 (2010).
Google Scholar
Reimer, T. et al. SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study. BMC Cancer 16, 337 (2016).
Google Scholar
Gracia, C. R. et al. Impact of cancer therapies on ovarian reserve. Fertil. Steril. 97, 134–40.e1 (2012).
Google Scholar
Thomas-Teinturier, C. et al. Ovarian reserve after treatment with alkylating agents during childhood. Hum. Reprod. 30, 1437–1446 (2015).
Google Scholar
Partridge, A. H. et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil. Steril. 94, 638–644 (2010).
Google Scholar
Pilsgaard, F. et al. The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling. Acta Obstet. Gynecol. Scand. 97, 1105–1113 (2018).
Google Scholar
Dewailly, D. & Laven, J. AMH as the primary marker for fertility. Eur. J. Endocrinol. 181, D45–D51 (2019).
Google Scholar
Moolhuijsen, L. M. E. & Visser, J. A. Anti-Mullerian hormone and ovarian reserve: update on assessing ovarian function. J. Clin. Endocrinol. Metab. 105, 3361–3373 (2020).
Google Scholar
Oktay, K. et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 36, 1994–2001 (2018).
Google Scholar
ESHRE Guideline Group on Female Fertility Preservation et al. ESHRE guideline: female fertility preservation. Hum. Reprod. Open 2020, hoaa052 (2020).
Google Scholar
Carrera, P. M., Kantarjian, H. M. & Blinder, V. S. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J. Clin. 68, 153–165 (2018).
Google Scholar
von Wolff, M. et al. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. Eur. J. Obstet. Gynecol. Reprod. Biol. 199, 146–149 (2016).
Google Scholar
Lambertini, M. et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J. Clin. Oncol. 36, 1981–1990 (2018).
Google Scholar
Chen, J. et al. Construction and cryopreservation of an artificial ovary in cancer patients as an element of cancer therapy and a promising approach to fertility restoration. Hum. Fertil. 25, 651–661 (2022).
Google Scholar
Arecco, L. et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum. Reprod. 37, 954–968 (2022).
Google Scholar
Chian, R. C., Uzelac, P. S. & Nargund, G. In vitro maturation of human immature oocytes for fertility preservation. Fertil. Steril. 99, 1173–1181 (2013).
Google Scholar
Wood, M. E. et al. Second malignant neoplasms: assessment and strategies for risk reduction. J. Clin. Oncol. 30, 3734–3745 (2012).
Google Scholar
Lyman, G. H. et al. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann. Oncol. 29, 1903–1910 (2018).
Google Scholar
Travis, L. B. Therapy-associated solid tumors. Acta Oncol. 41, 323–333 (2002).
Google Scholar
Ganz, P. A. & Casillas, J. N. Incorporating the risk for subsequent primary cancers into the care of adult cancer survivors: moving beyond 5-year survival. J. Am. Med. Assoc. 324, 2493–2495 (2020).
Google Scholar
Sung, H. et al. Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States. J. Am. Med. Assoc. 324, 2521–2535 (2020).
Google Scholar
Areethamsirikul, N. & Reece, D. E. The risk of secondary primary malignancies after therapy for multiple myeloma. Leuk. Lymphoma 56, 3012–3021 (2015).
Google Scholar
Castro, G. A., Church, A., Pechet, L. & Snyder, L. M. Leukemia after chemotherapy of Hodgkin’s disease. N. Engl. J. Med. 289, 103–104 (1973).
Google Scholar
Preisler, H. D. & Lyman, G. H. Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical features and response to therapy. Am. J. Hematol. 3, 209–218 (1977).
Google Scholar
Crump, M. et al. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3066–3071 (2003).
Google Scholar
Smith, R. E. et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J. Clin. Oncol. 21, 1195–1204 (2003).
Google Scholar
Praga, C. et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J. Clin. Oncol. 23, 4179–4191 (2005).
Google Scholar
Leone, G. et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92, 1389–1398 (2007).
Google Scholar
Le Deley, M. C. et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J. Clin. Oncol. 25, 292–300 (2007).
Google Scholar
Patt, D. A. et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J. Clin. Oncol. 25, 3871–3876 (2007).
Google Scholar
Josting, A. et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J. Clin. Oncol. 21, 3440–3446 (2003).
Google Scholar
Morton, L. M. et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975–2008. Blood 121, 2996–3004 (2013).
Google Scholar
Travis, L. B. et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J. Natl Cancer Inst. 87, 524–530 (1995).
Google Scholar
Mudie, N. Y. et al. Risk of second malignancy after non-Hodgkin’s lymphoma: a British Cohort Study. J. Clin. Oncol. 24, 1568–1574 (2006).
Google Scholar
Travis, L. B. et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J. Natl Cancer Inst. 94, 182–192 (2002).
Google Scholar
Travis, L. B. et al. Cancer survivorship–genetic susceptibility and second primary cancers: research strategies and recommendations. J. Natl Cancer Inst. 98, 15–25 (2006).
Google Scholar
Relling, M. V. et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101, 3862–3867 (2003).
Google Scholar
Hershman, D. et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J. Natl Cancer Inst. 99, 196–205 (2007).
Google Scholar
Lyman, G. H. et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J. Clin. Oncol. 28, 2914–2924 (2010).
Google Scholar
Smith, S. M. et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102, 43–52 (2003).
Google Scholar
Schaapveld, M. et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N. Engl. J. Med. 373, 2499–2511 (2015).
Google Scholar
Perez, D. G., Loprinzi, C. & Ruddy, K. J. Lifestyle factors can lead to multiple cancers over a lifetime-here we go again. JAMA Oncol. 7, 505–506 (2021).
Google Scholar
Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
Google Scholar
Bergerot, C. D. & Pal, S. K. Shining a light on the psychological burden of cancer. Nat. Med. 28, 637–638 (2022).
Google Scholar
Zabora, J. et al. The prevalence of psychological distress by cancer site. Psychooncology 10, 19–28 (2001).
Google Scholar
Institute of Medicine (US) Committee on Psychosocial Services to Cancer Patients/Families in a Community Setting. Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs (National Academies Press, 2008).
Riba, M. B. et al. Distress management, version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc Netw. 17, 1229–1249 (2019).
Google Scholar
Andersen, B. L. et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J. Clin. Oncol. 32, 1605–1619 (2014).
Google Scholar
Jacobsen, P. B., Wagner, L. I. & New, A. Quality standard: the integration of psychosocial care into routine cancer care. J. Clin. Oncol. 30, 1154–1159 (2012).
Google Scholar
Lebel, S. et al. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support. Care Cancer 24, 3265–3268 (2016).
Google Scholar
Bergerot, C. D. et al. Fear of cancer recurrence or progression: what is it and what can we do about it? Am. Soc. Clin. Oncol. Educ. Book 42, 1–10 (2022).
Google Scholar
Chang, W. H. & Lai, A. G. Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers. Nat. Med. 28, 860–870 (2022).
Google Scholar
Heinrich, M. et al. Suicide risk and mortality among patients with cancer. Nat. Med. 28, 852 (2022).
Google Scholar
Li, M., Fitzgerald, P. & Rodin, G. Evidence-based treatment of depression in patients with cancer. J. Clin. Oncol. 30, 1187–1196 (2012).
Google Scholar
Traeger, L. et al. Evidence-based treatment of anxiety in patients with cancer. J. Clin. Oncol. 30, 1197–1205 (2012).
Google Scholar
Bower, J. E. et al. Targeting depressive symptoms in younger breast cancer survivors: the pathways to wellness randomized controlled trial of mindfulness meditation and survivorship education. J. Clin. Oncol. 39, 3473–3484 (2021).
Google Scholar
McAlpine, H. et al. A systematic review of types and efficacy of online interventions for cancer patients. Patient Educ. Couns. 98, 283–295 (2015).
Google Scholar
Dossett, L. A. et al. The primary care provider (PCP)-cancer specialist relationship: a systematic review and mixed-methods meta-synthesis. CA Cancer J. Clin. 67, 156–169 (2017).
Google Scholar
Snyder, C. F. et al. Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordination. J. Cancer Surviv. 9, 641–649 (2015).
Google Scholar
Barone, B. B. et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300, 2754–2764 (2008).
Google Scholar
Griffiths, R. I., Keating, N. L. & Bankhead, C. R. Quality of diabetes care in cancer: a systematic review. Int. J. Qual. Health Care 31, 75–88 (2019).
Google Scholar
Halpern, M. T. et al. Models of cancer survivorship care: overview and summary of current evidence. J. Oncol. Pract. 11, e19–e27 (2015).
Google Scholar
Chan, R. J. et al. Outcomes of cancer survivorship education and training for primary care providers: a systematic review. J. Cancer Surviv. 16, 279–302 (2022).
Google Scholar
Earle, C. C. et al. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J. Clin. Oncol. 21, 1447–1451 (2003).
Google Scholar
Khan, N. F., Carpenter, L., Watson, E. & Rose, P. W. Cancer screening and preventative care among long-term cancer survivors in the United Kingdom. Br. J. Cancer 102, 1085–1090 (2010).
Google Scholar
Nekhlyudov, L., O’Malley, D. M. & Hudson, S. V. Integrating primary care providers in the care of cancer survivors: gaps in evidence and future opportunities. Lancet Oncol. 18, e30–e38 (2017).
Google Scholar
Bober, S. L. et al. Caring for cancer survivors: a survey of primary care physicians. Cancer 115, 4409–4418 (2009).
Google Scholar
Cheung, W. Y., Neville, B. A., Cameron, D. B., Cook, E. F. & Earle, C. C. Comparisons of patient and physician expectations for cancer survivorship care. J. Clin. Oncol. 27, 2489–2495 (2009).
Google Scholar
Alfano, C. M. et al. Building personalized cancer follow-up care pathways in the United States: lessons learned from implementation in England, Northern Ireland, and Australia. Am. Soc. Clin. Oncol. Educ. Book. 39, 625–639 (2019).
Google Scholar
Jones, J. M. et al. Readdressing the needs of cancer survivors during COVID-19: a path forward. J. Natl Cancer Inst. 113, 955–961 (2021).
Google Scholar
Qian, A. S. et al. Disparities in telemedicine during COVID-19. Cancer Med. 11, 1192–1201 (2022).
Google Scholar
Nekhlyudov, L. et al. Developing a quality of cancer survivorship care framework: implications for clinical care, research, and policy. J. Natl Cancer Inst. 111, 1120–1130 (2019).
Google Scholar
Chan, R. J. et al. Effectiveness and implementation of models of cancer survivorship care: an overview of systematic reviews. J. Cancer Surviv. 17, 197–221 (2021).
Google Scholar
McBride, C. M., Emmons, K. M. & Lipkus, I. M. Understanding the potential of teachable moments: the case of smoking cessation. Health Educ. Res. 18, 156–170 (2003).
Google Scholar
Demark-Wahnefried, W. et al. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J. Clin. Oncol. 23, 5814–5830 (2005).
Google Scholar
Brown, J. C. et al. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol. Biomark. Prev. 20, 123–133 (2011).
Google Scholar
Sweegers, M. G. et al. Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment? A systematic review and meta-analysis of randomised controlled trials. Br. J. Sports Med. 52, 505–513 (2018).
Google Scholar
Buffart, L. M. et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat. Rev. 52, 91–104 (2017).
Google Scholar
Brown, J. C. et al. The efficacy of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis. PLoS One 7, e30955 (2012).
Google Scholar
Dalla Via, J., Daly, R. M. & Fraser, S. F. The effect of exercise on bone mineral density in adult cancer survivors: a systematic review and meta-analysis. Osteoporos. Int. 29, 287–303 (2018).
Google Scholar
Mercier, J., Savard, J. & Bernard, P. Exercise interventions to improve sleep in cancer patients: a systematic review and meta-analysis. Sleep Med. Rev. 36, 43–56 (2017).
Google Scholar
Mitchell, S. A. & Chambers, D. A. Leveraging implementation science to improve cancer care delivery and patient outcomes. J. Oncol. Pract. 13, 523–529 (2017).
Google Scholar
Ramsey, S. D., Lyman, G. H. & Bangs, R. Addressing skyrocketing cancer drug prices comes with tradeoffs: pick your poison. JAMA Oncol. 2, 425–426 (2016).
Google Scholar
Desai, A. P. et al. Economic cost and sustainability of oral therapies in precision oncology. JCO Oncol. Pract. 18, e1247–e1254 (2022).
Google Scholar
Time. How Healthcare Costs Hurt American Workers and Benefit the Wealthy https://time.com/5785945/health-care-problems-america/ (20 February 2020).
Lyman, G. H. Counting the costs of cancer care. Lancet Oncol. 14, 1142–1143 (2013).
Google Scholar
Lyman, G. H. & Kuderer, N. Financial toxicity, financial abuse, or financial torture: let’s call it what it is! Cancer Invest. 38, 139–142 (2020).
Google Scholar
Knight, T. G. et al. Financial toxicity in adults with cancer: adverse outcomes and noncompliance. J. Oncol. Pract. https://doi.org/10.1200/JOP.18.00120 (2018).
Google Scholar
National Cancer Institute. Financial Toxicity. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/financial-toxicity (2023).
Huang, I. C. et al. Determinants and consequences of financial hardship among adult survivors of childhood cancer: a report from the St. Jude lifetime cohort study. J. Natl Cancer Inst. 111, 189–200 (2019).
Google Scholar
de Souza, J. A. et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 123, 476–484 (2017).
Google Scholar
Gilligan, A. M. et al. Death or Debt? National estimates of financial toxicity in persons with newly-diagnosed cancer. Am. J. Med. 131, 1187–1199.e5 (2018).
Google Scholar
Lyman, G. H., Zon, R. & Harvey, R. D. Rationale, opportunities, and reality of biosimilar medications. N. Engl. J. Med. 379, 694–695 (2018).
Google Scholar
Lyman, G. H. & Henk, H. J. Association of generic imatinib availability and pricing with trends in tyrosine kinase inhibitor use in patients with chronic myelogenous leukemia. JAMA Oncol. 6, 1969–1971 (2020).
Google Scholar
Rodriguez, G. et al. ASCO policy statement on biosimilar and interchangeable products in oncology. JCO Oncol. Pract. https://doi.org/10.1200/OP.22.00783 (2023).
Google Scholar
Schnipper, L. E. et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J. Clin. Oncol. 34, 2925–2934 (2016).
Google Scholar
Cherny, N. I. et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann. Oncol. 28, 2340–2366 (2017).
Google Scholar
Cherny, N. I. et al. Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score. J. Clin. Oncol. 37, 336–349 (2019).
Google Scholar
Schnipper, L. E. et al. American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J. Clin. Oncol. 33, 2563–2577 (2015).
Google Scholar
Tefferi, A. et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin. Proc. 90, 996–1000 (2015).
Google Scholar
Altice, C. K. et al. Financial hardships experienced by cancer survivors: a systematic review. J. Natl Cancer Inst. 109, djw205 (2017).
Google Scholar
Desai, A. & Gyawali, B. Financial toxicity of cancer treatment: moving the discussion from acknowledgement of the problem to identifying solutions. EClinicalMedicine 20, 100269 (2020).
Google Scholar
Witte, J. et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann. Oncol. 30, 1061–1070 (2019).
Google Scholar
United Nations. Universal Declaration of Human Rights https://www.un.org/en/about-us/universal-declaration-of-human-rights (1948).
National Academies of Sciences, Engineering, and Medicine. Integrating Social Care into the Delivery of Health Care: Moving Upstream to Improve the Nation’s Health (National Academies Press, 2019).
Moullin, J. C. et al. A systematic review of implementation frameworks of innovations in healthcare and resulting generic implementation framework. Health Res. Policy Syst. 13, 16 (2015).
Google Scholar
Colquhoun, H. et al. Towards a common terminology: a simplified framework of interventions to promote and integrate evidence into health practices, systems, and policies. Implement. Sci. 9, 51 (2014).
Google Scholar